BrightGene Presents Positive Phase 2 Data for Dual GLP-1R / GIPR Agonist for Weight Management and Type 2 Diabetes and Preclinical Data for Novel Amylin Analog at American Diabetes Association's 85th Scientific Sessions

Bright Gene Bahrain Iran Iraq Jordan Kuwait Lebanon Oman Palestine Qatar Saudi Arabia Syria United Arab Emirates Yemen China Illinois California

Phase 2 data highlights best-in-class potential of dual GLP-1R/GIPR agonist BGM0504 for weight management and metabolic risk reduction in individuals with type 2 diabetes and overweight, non-obese individualsPreclinical data for BGM1812 supports further development as next-generation amylin analog for obesity treatmentView original content:https://www.prnewswire.co.uk/news-releases/brightgene-presents-positive-phase-2-data-for-dual-glp-1rgipr-agonist-for-weight-management-and-type-2-diabetes-and-preclinical-data-for-novel-amylin-analog-at-american-diabetes-associations-85th-scientific-sessions-302488874.html